Literature DB >> 18485433

Arsenite-induced mitotic death involves stress response and is independent of tubulin polymerization.

B Frazier Taylor1, Samuel C McNeely, Heather L Miller, J Christopher States.   

Abstract

Arsenite, a known mitotic disruptor, causes cell cycle arrest and cell death at anaphase. The mechanism causing mitotic arrest is highly disputed. We compared arsenite to the spindle poisons nocodazole and paclitaxel. Immunofluorescence analysis of alpha-tubulin in interphase cells demonstrated that, while nocodazole and paclitaxel disrupt microtubule polymerization through destabilization and hyperpolymerization, respectively, microtubules in arsenite-treated cells remain comparable to untreated cells even at supra-therapeutic concentrations. Immunofluorescence analysis of alpha-tubulin in mitotic cells showed spindle formation in arsenite- and paclitaxel-treated cells but not in nocodazole-treated cells. Spindle formation in arsenite-treated cells appeared irregular and multi-polar. gamma-tubulin staining showed that cells treated with nocodazole and therapeutic concentrations of paclitaxel contained two centrosomes. In contrast, most arsenite-treated mitotic cells contained more than two centrosomes, similar to centrosome abnormalities induced by heat shock. Of the three drugs tested, only arsenite treatment increased expression of the inducible isoform of heat shock protein 70 (HSP70i). HSP70 and HSP90 proteins are intimately involved in centrosome regulation and mitotic spindle formation. HSP90 inhibitor 17-DMAG sensitized cells to arsenite treatment and increased arsenite-induced centrosome abnormalities. Combined treatment of 17-DMAG and arsenite resulted in a supra-additive effect on viability, mitotic arrest, and centrosome abnormalities. Thus, arsenite-induced abnormal centrosome amplification and subsequent mitotic arrest is independent of effects on tubulin polymerization and may be due to specific stresses that are protected against by HSP90 and HSP70.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18485433      PMCID: PMC2504415          DOI: 10.1016/j.taap.2008.02.030

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  60 in total

1.  The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel.

Authors:  M M Malingré; J H Beijnen; H Rosing; F J Koopman; O van Tellingen; K Duchin; W W ten Bokkel Huinink; M Swart; J Lieverst; J H Schellens
Journal:  Anticancer Drugs       Date:  2001-04       Impact factor: 2.248

2.  Stress-related gene expression in mice treated with inorganic arsenicals.

Authors:  J Liu; M B Kadiiska; Y Liu; T Lu; W Qu; M P Waalkes
Journal:  Toxicol Sci       Date:  2001-06       Impact factor: 4.849

3.  A constitutive 70 kDa heat-shock protein is localized on the fibres of spindles and asters at metaphase in an ATP-dependent manner: a new chaperone role is proposed.

Authors:  C Agueli; F Geraci; G Giudice; L Chimenti; D Cascino; G Sconzo
Journal:  Biochem J       Date:  2001-12-01       Impact factor: 3.857

4.  Sensitivity of myelomonocytic leukemia cells to arsenite-induced cell cycle disruption, apoptosis, and enhanced differentiation is dependent on the inter-relationship between arsenic concentration, duration of treatment, and cell cycle phase.

Authors:  M J McCabe; K P Singh; S A Reddy; B Chelladurai; J G Pounds; J J Reiners; J C States
Journal:  J Pharmacol Exp Ther       Date:  2000-11       Impact factor: 4.030

5.  Requirement of Hsp90 for centrosomal function reflects its regulation of Polo kinase stability.

Authors:  G de Cárcer; M do Carmo Avides; M J Lallena; D M Glover; C González
Journal:  EMBO J       Date:  2001-06-01       Impact factor: 11.598

6.  History of the development of arsenic derivatives in cancer therapy.

Authors:  S Waxman; K C Anderson
Journal:  Oncologist       Date:  2001

Review 7.  Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies.

Authors:  A J Murgo
Journal:  Oncologist       Date:  2001

8.  Introduction: the history of arsenic trioxide in cancer therapy.

Authors:  K H Antman
Journal:  Oncologist       Date:  2001

9.  Arsenite disrupts mitosis and induces apoptosis in SV40-transformed human skin fibroblasts.

Authors:  J Christopher States; John J Reiners; Joel G Pounds; David J Kaplan; Brian D Beauerle; Samuel C McNeely; Patricia Mathieu; Michael J McCabe
Journal:  Toxicol Appl Pharmacol       Date:  2002-04-15       Impact factor: 4.219

10.  Drug approval summaries: arsenic trioxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene.

Authors:  M H Cohen; S Hirschfeld; S Flamm Honig; A Ibrahim; J R Johnson; J J O'Leary; R M White; G A Williams; R Pazdur
Journal:  Oncologist       Date:  2001
View more
  13 in total

1.  Precancerous and non-cancer disease endpoints of chronic arsenic exposure: the level of chromosomal damage and XRCC3 T241M polymorphism.

Authors:  Manjari Kundu; Pritha Ghosh; Sanhita Mitra; J K Das; T J Sau; Saptarshi Banerjee; J Christopher States; Ashok K Giri
Journal:  Mutat Res       Date:  2010-10-28       Impact factor: 2.433

Review 2.  Aneuploidy as an early mechanistic event in metal carcinogenesis.

Authors:  Sandra S Wise; John Pierce Wise
Journal:  Biochem Soc Trans       Date:  2010-12       Impact factor: 5.407

Review 3.  Mechanisms of metal-induced centrosome amplification.

Authors:  Amie L Holmes; John Pierce Wise
Journal:  Biochem Soc Trans       Date:  2010-12       Impact factor: 5.407

4.  Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses.

Authors:  Clarisse S Muenyi; Allan R Pinhas; Teresa W Fan; Guy N Brock; C William Helm; J Christopher States
Journal:  Toxicol Sci       Date:  2012-02-13       Impact factor: 4.849

Review 5.  Disruption of Mitotic Progression by Arsenic.

Authors:  J Christopher States
Journal:  Biol Trace Elem Res       Date:  2015-03-22       Impact factor: 3.738

6.  Suppression of p53 and p21CIP1/WAF1 reduces arsenite-induced aneuploidy.

Authors:  Ana María Salazar; Heather L Miller; Samuel C McNeely; Monserrat Sordo; Patricia Ostrosky-Wegman; J Christopher States
Journal:  Chem Res Toxicol       Date:  2010-02-15       Impact factor: 3.739

7.  Cisplatin plus sodium arsenite and hyperthermia induces pseudo-G1 associated apoptotic cell death in ovarian cancer cells.

Authors:  Clarisse S Muenyi; Abhaya P Trivedi; C William Helm; J Christopher States
Journal:  Toxicol Sci       Date:  2014-02-11       Impact factor: 4.849

8.  Mitotic arrest-associated apoptosis induced by sodium arsenite in A375 melanoma cells is BUBR1-dependent.

Authors:  Samuel C McNeely; B Frazier Taylor; J Christopher States
Journal:  Toxicol Appl Pharmacol       Date:  2008-04-09       Impact factor: 4.219

9.  Chronic exposure to zinc chromate induces centrosome amplification and spindle assembly checkpoint bypass in human lung fibroblasts.

Authors:  Amie L Holmes; Sandra S Wise; Stephen C Pelsue; AbouEl-Makarim Aboueissa; Wilma Lingle; Jeffery Salisbury; Jamie Gallagher; John Pierce Wise
Journal:  Chem Res Toxicol       Date:  2010-02-15       Impact factor: 3.739

10.  Diverse system stresses: common mechanisms of chromosome fragmentation.

Authors:  J B Stevens; B Y Abdallah; G Liu; C J Ye; S D Horne; G Wang; S Savasan; M Shekhar; S A Krawetz; M Hüttemann; M A Tainsky; G S Wu; Y Xie; K Zhang; H H Q Heng
Journal:  Cell Death Dis       Date:  2011-06-30       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.